Learn about the symptoms of leukemia, how it’s diagnosed, and what therapies modern medicine offers for blood cancer. Facts, advice, and support.
Table of Contents
- What is leukemia? Definition and classification
- First symptoms of leukemia – what to look out for?
- Leukemia diagnostics – key tests and their significance
- Acute and chronic leukemia: differences in diagnosis and treatment
- Modern leukemia treatments – transplantation, chemotherapy and new therapies
- Support after diagnosis and perspectives for leukemia patients
What is leukemia? Definition and classification
Leukemia is a general term for a group of malignant neoplasms of the hematopoietic system that arise within the bone marrow and lead to an uncontrolled proliferation of immature blood cells, known as blasts. This process results in a disturbance of the balance between healthy and cancerous blood cells, negatively affecting the functioning of the entire organism. The cancerous cells are unable to perform their normal physiological functions, such as oxygen transport, defense against infections, or prevention of hemorrhages. At the same time, excessive proliferation of blasts in the marrow displaces healthy cell lines, leading to anemia, thrombocytopenia, and leukopenia, as well as numerous hematological and systemic complications. Leukemias comprise a diverse group of diseases in terms of causes, clinical course, and prognosis. The most important risk factors include genetic predisposition, exposure to ionizing radiation or chemicals, certain congenital syndromes, and chronic viral infections, although in most cases, the cause remains unknown. Leukemia typically follows a multi-symptomatic, often initially subtle course, which can mimic other, less serious illnesses, making early diagnosis challenging.
Clinically and morphologically, leukemias are classified primarily based on the speed of disease progression and the type of affected cells. The key distinction is between acute and chronic leukemias. Acute leukemias, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), are characterized by a sudden onset and rapid escalation of symptoms, as highly immature blast cells proliferate. Without immediate treatment, they quickly progress to life-threatening failure of the hematopoietic system. Chronic leukemias, including chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL), develop slowly, often over months or years, and initial symptoms are either non-specific or absent. Leukemias are also divided based on the cell line from which malignant cells originate: lymphoblastic (lymphoid), derived from abnormal precursors of lymphocytes, and myeloid (myelogenous), derived from precursors of other marrow cells. This results in the four main types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), though rarer, mixed, or intermediate forms have now also been identified through detailed molecular and cytogenetic studies. In addition to the traditional classification, modern hematology also considers prognostic factors such as the presence of certain genetic mutations, chromosomal abnormalities (e.g., the BCR-ABL mutation in CML), and response to therapy, allowing for better outcome predictions and optimal treatment strategies. Leukemia, therefore, is not a single disease but a complex syndrome, requiring advanced differential diagnosis and individualized treatment approaches.
First symptoms of leukemia – what to look out for?
Due to its complex pathogenesis and diverse variants, leukemia can manifest in many ways. Importantly, the first symptoms are often non-specific, misleading, and can be easily overlooked—both by the patient and general practitioners. In the early phase, the most noticeable sign is a general decline in immunity and physical capacity. The most common symptoms are chronic fatigue, weakness, trouble concentrating, and reduced exercise tolerance, which are easily attributed to everyday stress or overwork. Another significant warning sign is recurrent infections—colds, tonsillitis, pneumonia, and bronchitis—arising without clear cause and more frequently than normal, indicating disruption in blood immune mechanisms. Additionally, many patients develop distinctive changes in blood count, such as anemia (anemia), which manifests as pale skin and mucous membranes, shortness of breath, palpitations, or even fainting.
Another critical element is the tendency to bruise or bleed easily—even after minor trauma, or even spontaneously, like gum or nosebleeds. This is due to impaired platelet production (thrombocytopenia), one of the hallmark symptoms of leukemia. In children and adolescents, recurrent bone and joint pain—which may limit mobility—should raise concern, as these result from excessive proliferation of leukemia cells in the marrow. Enlarged lymph nodes, spleen, or liver may also occur, often gradually—patients may notice painless lumps under the skin on the neck, underarms, or groin, as well as discomfort, a feeling of fullness, or pain in the left upper abdomen due to spleen enlargement. Additional symptoms like night sweats, unexplained prolonged fever, sudden weight loss, or itchy skin should also increase vigilance. Although these symptoms are not specific, their simultaneous occurrence or unusual frequency/intensity should prompt immediate blood testing and hematological consultation. Leukemia is also characterized by the gradual onset of symptoms, which may remain unnoticed for a long time, especially with chronic forms. This masked character means many patients only see a doctor at advanced stages, hindering treatment. Therefore, it is vital not to ignore any recurring or prolonged symptoms, however mild, with no clear cause—this applies to both adults and children. In everyday practice, unusual health changes, decreased endurance, ongoing infections, or persistent bruising should prompt extended hematological diagnostics, especially in previously healthy individuals.
Leukemia diagnostics – key tests and their significance
The diagnostic process for leukemia is complex and multi-stage, due to the non-specific nature of its symptoms and the need for differential diagnosis with other hematological and systemic diseases. Diagnosis usually starts with a medical interview and basic blood laboratory tests, such as a peripheral blood smear, which may reveal abnormal blood cells (blasts), low counts or qualitative anomalies of erythrocytes, leukocytes, and platelets. In addition to the blood count, ESR, CRP, and fibrinogen levels help assess inflammation and exclude infections or other health issues. Flow cytometry is also essential, providing a precise characterization of malignant cells and their immunophenotype. This technique distinguishes the type of leukemia (e.g., lymphoblastic vs. myeloid) and identifies prognostic markers for therapy selection. Next, bone marrow aspiration and trephine biopsy are indispensable for confirming leukemia, assessing the presence and percentage of blasts in the marrow, and enabling detailed molecular and genetic testing. Cytogenetic analysis (karyotyping) helps identify characteristic chromosomal changes, such as t(9;22) (Philadelphia chromosome) in CML, or other translocations and deletions, which, in addition to diagnostic value, provide prognostic and therapeutic guidance. Molecular diagnostics using PCR, FISH, and sequencing detect mutations or gene fusions, supporting minimal residual disease (MRD) monitoring and treatment personalization. Imaging studies such as abdominal ultrasound and CT scans assess organ enlargement (spleen, liver), enlarged lymph nodes, or organ infiltration. In atypical cases or with specific symptoms, a lumbar puncture may assess for leukemia cells in cerebrospinal fluid, especially if CNS involvement is suspected—as in acute lymphoblastic leukemia. Diagnostics are performed mainly in hematology or oncohematology departments by multidisciplinary teams, including hematologists, laboratory diagnosticians, cytologists, and molecular geneticists. Comprehensive diagnostics enable not just leukemia type and stage identification, but also risk factor evaluation and tailored treatment planning according to the individual disease biology of each patient.
An essential part of leukemia diagnostics is also monitoring treatment responses and detecting possible relapses. As modern medicine offers increasingly sensitive methods for minimal residual disease detection, regular molecular and immunophenotypic testing allows for fast therapeutic intervention when even small amounts of leukemia cells escape traditional methods. Molecular tumor profiling at diagnosis is gaining importance, allowing predictable responses to targeted treatments, immunotherapy, or bone marrow transplantation. Recent years have seen advances in molecular biology and bioinformatics in leukemia diagnostics, enabling personalized treatments precisely targeting abnormal pathways and driver mutations. Genetic disruptions, such as NRAS, FLT3, NPM1, TP53 mutations, or BCR-ABL1 aberrations, can determine clinical course and affect therapy choices and patient prognosis. Evaluation of organ functions (liver, kidneys), coagulation indices, uric acid, and electrolytes is also essential—especially prior to intensive cytostatic therapy. This comprehensive diagnostic approach not only supports quick and accurate diagnosis but also optimizes subsequent therapy, reduces complications, and increases the chance of effective disease remission.
Acute and chronic leukemia: differences in diagnosis and treatment
Leukemias are primarily classified as acute or chronic, and fundamental differences exist between these two categories regarding clinical presentation, progression, diagnosis, and treatment. Acute leukemias (such as acute myeloid leukemia – AML and acute lymphoblastic leukemia – ALL) progress rapidly, with symptoms appearing suddenly—often over weeks—as immature cancer cells (blasts) accumulate in the bone marrow and blood. Dramatic impairment of body function follows, manifested by severe anemia, frequent mucosal bleeding, propensity to infections due to immune compromise, fever, and organ enlargement (liver, spleen). Diagnosis of acute leukemia requires urgent blood counts (marked leukocytosis or pancytopenia with blasts present), flow cytometry, marrow smear, and detailed cytogenetic and molecular analysis. Immediate treatment is often necessary, as delay can quickly lead to life-threatening deterioration. In contrast, chronic leukemias (e.g., chronic lymphocytic leukemia – CLL and chronic myeloid leukemia – CML) develop insidiously over years and are often detected incidentally during routine blood checks. Their progression is slow; early symptoms such as long-term fatigue, night sweats, or lymph node swelling may be minor or absent. Many patients with chronic leukemia do not require immediate treatment—“watch & wait” (active surveillance) is often employed until clear clinical or laboratory progression occurs.
Treatment of acute leukemias requires prompt, intensive chemotherapy to achieve remission and eradicate malignant cells. Therapy typically involves induction, consolidation, and maintenance phases, and for selected patients, allogeneic stem cell transplantation is considered, especially if poor prognostic features are present (such as specific genetic mutations, treatment resistance, or rapid relapse). Protocol intensity depends on general health, age, and comorbidities, with treatment often conducted as inpatient care in hematology wards. For acute leukemias, modern options like targeted therapy and immunotherapy—including kinase inhibitors, monoclonal antibodies, and CAR-T cell treatments—are emerging and significantly improving prognosis. Treatment for chronic leukemia is different, frequently initiated only upon symptom progression or laboratory evidence of significant disease. For example, tyrosine kinase inhibitors (TKIs) have revolutionized CML, halting cancer cell expansion by blocking key signalling pathways (e.g., the Philadelphia chromosome or BCR-ABL). Such therapies can be given on an outpatient basis, allowing long-term remission and improved quality of life versus aggressive chemotherapy. In CLL, mainstays are monoclonal antibodies, targeted agents (Bruton’s kinase or BCL-2 inhibitors), and, for some, chemoimmunotherapy. Precision monitoring of minimal residual disease (MRD) and genetic risk factors (e.g., deletions, TP53 mutations) is paramount for optimal, stage-adapted management. The differences in diagnosis and treatment for acute versus chronic leukemia reflect their distinct dynamics, prognosis, and therapy options, and advances in molecular diagnostics and targeted therapies have greatly improved outcomes for many patients in recent years.
Modern leukemia treatments – transplantation, chemotherapy and new therapies
Leukemia treatment is evolving dynamically, giving patients access to increasingly effective and less invasive therapies. The most common and still standard approach for acute leukemias remains multi-phase chemotherapy. Treatment consists of induction, consolidation, and maintenance phases. The initial goal is rapid elimination of cancer cells from the blood and marrow, while consolidation and maintenance secure results and minimize relapse risk. Protocols are tailored individually, according to leukemia subtype, patient condition, and genetic features, optimizing efficacy and minimizing side effects. In recent years, combination therapies—merging standard chemotherapy with targeted agents, immunotherapies, and modern monoclonal antibodies—have become standard practice. Beyond traditional cytostatics, drugs targeting specific cancer cell signaling pathways, like tyrosine kinase inhibitors for chronic myeloid leukemia, are increasingly important. This therapeutic breakthrough enables disease control for many without aggressive chemotherapy or transplantation, improving both life quality and disease-free survival.
Hematopoietic stem cell transplantation—commonly called bone marrow transplantation—is the most advanced and invasive option for selected leukemia patients, especially those with high relapse risk or resistance to standard regimens. The essence of transplantation is replacing damaged marrow with healthy, functioning cells from a donor (allogeneic transplant) or from the patient themselves (autologous transplant). Modern medicine uses sophisticated HLA matching to minimize complications, like graft-versus-host disease. Transplantation is preceded by intensive chemotherapy, sometimes combined with radiotherapy, to eradicate cancer cells before introducing healthy stem cells. In addition to traditional transplants, genetic engineering therapies are gaining significance. Innovative CAR-T immunotherapy—a technique involving modification of the patient’s own T lymphocytes to selectively destroy leukemia cells—has produced breakthrough results in resistant acute lymphoblastic leukemia where other therapies have failed. Immunotherapy with monoclonal antibodies is also rapidly developing; these agents precisely recognize and block antigens on cancer cells, triggering immune destruction. Additionally, inhibitors of BCL-2 proteins, immune checkpoints, and other vital molecules are increasingly used. The clinical practice now often employs combination therapies—integrating different action mechanisms—which improves efficacy and reduces toxicity. Advanced lab technology and detailed molecular profiling allow MRD monitoring and individualized management at every stage of treatment, reflecting the trend toward targeted, less burdensome leukemia therapies. An ever-expanding repertoire of modern therapies now enables long-term remissions and, in many cases, complete cures for patients with these complex blood cancers.
Support after diagnosis and perspectives for leukemia patients
Receiving a leukemia diagnosis is a turning point for patients and their loved ones. Initial stages are often marked by shock, uncertainty, and fear for the future. Comprehensive patient support then becomes a key part of therapy and includes not just medical care but also psychological, social, and practical help. Swift referral to specialized hematological centers and access to an experienced medical team facilitate better understanding of the disease, review of available treatments, and assessment of prognostic factors. Today, more centers offer multidisciplinary care—oncologists, hematologists, psychologists, and nurses work together to provide a personalized approach. This includes patient education on their leukemia course, side effects, infection prevention, hygiene in daily living, and coping with fatigue and anemia.
Psychological support is increasingly emphasized—a psycho-oncologist provides individual or group consultations, stress management, mood change counseling, and helps families adjust. Support groups and patient foundations are also crucial—they provide a platform for sharing experiences, information about therapies and social benefits, access to clinical trials, and assistance finding appropriate care facilities or drug programs. Proper psychoeducation enables patients to adapt better to long-term treatment, build motivation, and maintain control over their lives despite illness.
Prospects for leukemia patients have drastically improved in recent years due to advances in molecular diagnostics, the development of targeted therapies, and the introduction of novel drugs such as tyrosine kinase inhibitors and CAR-T immunotherapy. Rapid and accurate diagnosis, along with personalized therapy tailored to molecular profiles, significantly enhances treatment effectiveness, leading to longer remissions and even complete cures, especially for younger patients and those with favorable prognostic factors. In chronic leukemias, such as CML and CLL, the disease often resembles other chronic illnesses that are effectively pharmacologically managed for years, without intensive hospitalizations or radical procedures. Many patients return to normal daily activities, work, and studies. However, long-term care involves regular blood parameter checks, MRD monitoring, and relapse risk evaluation. For acute leukemia—especially those with poor genetic features—outcomes can still be challenging, yet the implementation of innovative therapies is leading to higher remission rates and improved life quality even in advanced stages. Ongoing psychological support, nutritional optimization, and integration with family and community significantly impact emotional stability and treatment tolerance. New systemic initiatives, such as early complication detection programs, social assistance, and tailored care for post-transplant patients, are crucial for maintaining high quality of life. Telemedicine and remote health monitoring now play an increasing role, ensuring ongoing medical team contact and rapid reactions to complications. Ultimately, post-diagnosis leukemia support—understood as comprehensive, interdisciplinary care—not only minimizes complications and improves outcomes but also fosters patient independence, social engagement, and satisfaction with life despite living with chronic cancer.
Summary
Leukemia is a blood cancer where early detection greatly increases the chance of successful treatment. Recognizing symptoms and prompt diagnostics—including blood tests, smears, and marrow studies—are crucial for proper therapy. Modern hematology offers a range of treatments: from standard chemotherapy and bone marrow transplantation to innovative targeted therapies. Psychological support and specialized post-diagnosis care play an essential role in enhancing patients’ quality of life. Remember: education, quick action, and access to therapy are the best ways to fight leukemia effectively.
